MSD Australia will next month significantly reduce the price of its Zepatier (elbasivir/grazoprevir) medication for Hepatitis C.
The $12,600 difference in price will see MSD honour claims for pharmacy stock on hand, but affected pharmacies must submit claims to their wholesalers by 07 Dec 2018 to be eligible.
According to an update from the Pharmacy Guild of Australia, credits will be issued for unopened packets of Zepatier as of 30 Nov.
Pharmacies must provide a screen shot/print screen of their in-house inventory systems confirming the quantities of affected products.
The screen shot must include the date it is taken (30 Nov 2018), the product/product description and the quantity in stock.
Claims should be sent to wholesalers by email with the subject "MSD SOH Claim -
API, Sigma, Symbion, CHS and CH2 have all been briefed on the procedures and are ready to pass on claims to MSD once they are received early next month.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Nov 18
